共 50 条
- [21] The identification and pharmacological evaluation of potent, selective and orally available ACC1 inhibitorBIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (23)Mizojiri, RyoAsano, MoriteruSasaki, MasakoSatoh, YoshihikoYamamoto, YukikoSumi, HiroyukiMaezaki, Hironobu
- [22] Pharmacological characterization of the potent, selective and orally active cathepsin K inhibitor MIV-711BONE, 2012, 50 : S164 - S165Grabowska, U.Henderson, I.Edlund, M.Vrang, L.Sedig, S.Terelius, Y.Wikstrom, K.Sahlberg, B. -L.Chambers, T.Lindstrom, E.
- [23] Discovery and preclinical evaluation of AMG 397, a potent, selective and orally bioavailable MCL1 inhibitorCANCER RESEARCH, 2020, 80 (16)Caenepeel, SeanKaren, RexBelmontes, BrianVerlinsky, AllaTan, HongYang, YajingChen, XiaoyueLi, KexueAllen, JenniferWahlstrom, JanCanon, JudeCoxon, AngelaHughes, Paul
- [24] The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with VenetoclaxCANCERS, 2019, 11 (06):Tarantelli, ChiaraGaudio, EugenioHillmann, PetraSpriano, FilippoSartori, GiulioAresu, LucaCascione, LucianoRageot, DeniseKwee, IvoBeaufils, FlorentZucca, EmanueleStathis, AnastasiosWymann, Matthias P.Cmiljanovic, VladimirFabbro, DorianoBertoni, Francesco
- [25] Strategic Fluorination to Achieve a Potent, Selective, Metabolically Stable, and Orally Bioavailable Inhibitor of CSNK2MOLECULES, 2024, 29 (17):Ong, Han WeeYang, XuanSmith, Jeffery L.Taft-Benz, SharonHowell, StefanieDickmander, Rebekah J.Havener, Tammy M.Sanders, Marcia K.Brown, Jason W.Counago, Rafael M.Chang, EdconKraemer, AndreasMoorman, Nathaniel J.Heise, MarkAxtman, Alison D.Drewry, David H.Willson, Timothy M.
- [26] Pharmacological characterization of MK-3207, a potent and orally bioavailable CGRP receptor antagonistCEPHALALGIA, 2009, 29 : 139 - 139Salvatore, C. A.Moore, E. L.Hershey, J. C.Lynch, J. J.Regan, C. P.Bell, I. M.Gallicchio, S. N.Graham, S. L.Selnick, H. G.Vacca, J. P.Kane, S. A.
- [27] Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase InhibitorACS MEDICINAL CHEMISTRY LETTERS, 2010, 1 (03): : 120 - 124Gillman, Kevin W.Starrett, John E., Jr.Parker, Michael F.Xie, KaiBronson, Joanne J.Marcin, Lawrence R.McElhone, Kate E.Bergstrom, Carl P.Mate, Robert A.Williams, RichardMeredith, Jere E., Jr.Burton, Catherine R.Barten, Donna M.Toyn, Jeremy H.Roberts, Susan B.Lentz, Kimberley A.Houston, John G.Zaczek, RobertAlbright, Charles F.Decicco, Carl P.Macor, John E.Olson, Richard E.
- [28] OXA-01, a novel potent mTORC1/TORC2 inhibits displays imporved anti-tumor activity in comparison to rapamycin, and mTORC1 selective inhibitorCANCER RESEARCH, 2009, 69Gokhale, PrafullaBhagwat, ShripadCrew, AndrewCooke, AndrewMantis, ChristineWorkman, JenniferLandfair, DarlaBittner, MarkSennello, ReginaHart, KarenYoung, DavidArnold, LeeEpstein, DavidPachter, JonathanWild, Robert
- [29] Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1RJOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (17) : 9888 - 9911Czako, BarbaraMarszalek, Joseph. R.Burke, Jason P.Mandal, PijusLeonard, Paul G.Cross, Jason B.Mseeh, FaikaJiang, YongyingChang, Edward Q.Suzuki, ErikaKovacs, Jeffrey J.Feng, NingpingGera, SonalHarris, Angela L.Liu, ZhenMullinax, Robert A.Pang, JihaiParker, Connor A.Spencer, Nakia D.Yu, Simon S.Wu, QiTremblay, Martin R.Mikule, KeithWilcoxen, KeithHeffernan, Timothy P.Draetta, Giulio F.Jones, Philip
- [30] Discovery of GNE-6893, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of HPK1ACS MEDICINAL CHEMISTRY LETTERS, 2024, 15 (09): : 1606 - 1614Tellis, John C.Wei, BinQingSiu, MichaelAn, LeChan, Grace KayanChen, YongDu, XiangnanGazzard, LewisHu, BaihuaKiefer, JamesKakiuchi-Kiyota, SatokoLainchbury, MichaelLinehan, Jonathan L.Luo, XifengMalhotra, SushantMendonca, RohanPang, JodieRan, YinqingSethuraman, VijaySeward, EileenSneeringer, ChrisSu, DianWang, WeiruWu, PingMoffat, John G.Heffron, Timothy P.Choo, Edna F.Chan, Bryan K.